HC Wainwright reaffirmed their buy rating on shares of TransCode Therapeutics (NASDAQ:RNAZ – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock. TransCode Therapeutics Stock Performance TransCode Therapeutics stock opened at $1.78 on Wednesday. TransCode Therapeutics has a 52-week low of $0.42 […]